Simvastatin treatment preserves synaptic plasticity in AβPPswe/PS1dE9 mice

Journal of Alzheimer's Disease

Volumn 39, Issue 2, 2014, Pages 315-329

  Métais, Charles ^a   Brennan, Kathryn ^a   Mably, Alex J ^a,b   Scott, Michael ^a   Walsh, Dominic M ^a,b   Herron, Caroline E ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Alzheimer's disease; amyloid ; hippocampus; long term potentiation; statin

Indexed keywords

AMYLOID BETA PROTEIN; GLYCOGEN SYNTHASE KINASE 3; PRESENILIN 1; PROTEIN KINASE B; SIMVASTATIN; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET SUPPLEMENTATION; DRUG EFFECT; FEMALE; LONG TERM POTENTIATION; MALE; MOLECULAR BIOLOGY; MOUSE; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ALZHEIMER'S DISEASE; AMYLOID-Β; HIPPOCAMPUS; LONG-TERM POTENTIATION; STATIN;

AGE FACTORS; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LONG-TERM POTENTIATION; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEURONAL PLASTICITY; NOOTROPIC AGENTS; PHOSPHORYLATION; PRESENILIN-1; PROTO-ONCOGENE PROTEINS C-AKT; SIMVASTATIN; SYNAPSES; TAU PROTEINS;

EID: 84893971757     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-130257     Document Type: Article

References (84)

1. Saheki A, Terasaki T, Tamai I, Tsuji A (1994) In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm Res 11, 305-311.
2. Jones PH (2003) Comparing HMG-CoA reductase inhibitors. Clin Cardiol 26, I15-I20.
3. Tong XK, Nicolakakis N, Fernandes P, Ongali B, Brouillette J, Quirion R, Hamel E (2009) Simvastatin improves cerebrovascular function and counters soluble amyloid-beta, inflammation and oxidative stress in aged APP mice. Neurobiol Dis 35, 406-414.
4. Li L, Cao D, Kim H, Lester R, Fukuchi K (2006) Simvastatin enhances learning and memory independent of amyloid load in mice. Ann Neurol 60, 729-739.
5. Lu D, Qu C, GoussevA, Jiang H, Lu C, Schallert T, Mahmood A, Chen J, Li Y, Chopp M (2007) Statins increase neurogenesis in the dentate gyrus, reduce delayed neuronal death in the hippocampal CA3 region, and improve spatial learning in rat after traumatic brain injury. J Neurotrauma 24, 1132-1146.
6. Vaughan CJ (2003) Prevention of stroke and dementia with statins: Effects beyond lipid lowering. Am J Cardiol 91, 23B-29B.
7. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57, 1439-1443.
8. Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE (2007) Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med 5, 20.
9. Chen J, Zhang ZG, Li Y,Wang Y,Wang L, Jiang H, Zhang C, Lu M, Katakowski M, Feldkamp CS, ChoppM(2003) Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 53, 743-751.
10. Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH, Aisen PS (2011) A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 77, 556-563.
11. Buxbaum JD, Cullen EI, Friedhoff LT (2002) Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer betaamyloid peptide in vitro and in patients. Front Biosci 7, a50-a59.
12. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA (2000) Statins and the risk of dementia. Lancet 356, 1627-1631.
13. Collins R (2002) Heart protection study finds simvastatin reduces vascular risk in a wide range of high-risk patients. Am J Manag Care Suppl 6.
14. Shepherd J, Barter P (2002) Lipid-lowering-translating evidence into benefits. Atheroscler Suppl 2, 1-3.
15. Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, Welsh-Bohmer KA, Breitner JC (2005) Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 62, 217-224.
16. Allsop D, Yamamoto T, Kametani F, Miyazaki N, Ishii T (1991) Alzheimer amyloid beta/A4 peptide binding sites and a possible 'APP-secretase' activity associated with rat brain cortical membranes. Brain Res 551, 1-9.
17. Selkoe DJ (1991) The molecular pathology of Alzheimer's disease. Neuron 6, 487-498.
18. Shankar GM,Walsh DM (2009) Alzheimer's disease: Synaptic dysfunction and Abeta. Mol Neurodegener 4, 48.
19. Haass C, Hung AY, Schlossmacher MG, Oltersdorf T, Teplow DB, Selkoe DJ (1993) Normal cellular processing of the beta-amyloid precursor protein results in the secretion of the amyloid beta peptide and related molecules. Ann N Y Acad Sci 695, 109-116.
20. Xiong H, Callaghan D, Jones A, Walker DG, Lue LF, Beach TG, Sue LI, Woulfe J, Xu H, Stanimirovic DB, Zhang W (2008) Cholesterol retention in Alzheimer's brain is responsible for high beta-and gamma-secretase activities and Abeta production. Neurobiol Dis 29, 422-437.
21. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, SimonsK(1998) Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A 95, 6460-6464.
22. Xiu J, Nordberg A, Qi X, Guan ZZ (2006) Influence of cholesterol and lovastatin on alpha-form of secreted amyloid precursor protein and expression of alpha7 nicotinic receptor on astrocytes. Neurochem Int 49, 459-465.
23. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, von Bergmann K, Hennerici M, Beyreuther K, Hartmann T (2001) Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A 98, 5856-5861.
24. Kojro E, Gimpl G, Lammich S, MarzW, Fahrenholz F (2001) Lowcholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc Natl Acad Sci U S A 98, 5815-5820.
25. Cheng H, Vetrivel KS, Gong P, Meckler X, Parent A, Thinakaran G (2007) Mechanisms of disease: New therapeutic strategies for Alzheimer's disease-targeting APP processing in lipid rafts. Nat Clin Pract Neurol 3, 374-382.
26. Cordy JM, Hussain I, Dingwall C, Hooper NM, Turner AJ (2003) Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc Natl Acad Sci U S A 100, 11735-11740.
27. Ehehalt R, Keller P, Haass C, Thiele C, Simons K (2003) Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 160, 113-123.
28. Lee CY, Tse W, Smith JD, Landreth GE (2011) Apolipoprotein E promotes beta-amyloid trafficking and degradation by modulating microglial cholesterol levels. J Biol Chem 287, 2032-2044.
29. Barrett PJ, Song Y, Van Horn WD, Hustedt EJ, Schafer JM, Hadziselimovic A, Beel AJ, Sanders CR (2012) The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. Science 336, 1168-1171.
30. Yanagisawa K, Matsuzaki K (2002) Cholesterol-dependent aggregation of amyloid beta-protein. Ann N Y Acad Sci 977, 384-386.
31. Shankar GM, Leissring MA, Adame A, Sun X, Spooner E, Masliah E, Selkoe DJ, Lemere CA, Walsh DM (2009) Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life. Neurobiol Dis 36, 293-302.
32. Jo J, Whitcomb DJ, Olsen KM, Kerrigan TL, Lo SC, Bru-Mercier G, Dickinson B, Scullion S, Sheng M, Collingridge G, Cho K (2011) Abeta(1-42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3beta. Nat Neurosci 14, 545-547.
33. Peineau S, Taghibiglou C, Bradley C, Wong TP, Liu L, Lu J, Lo E,Wu D, Saule E, Bouschet T, Matthews P, Isaac JT, Bortolotto ZA, Wang YT, Collingridge GL (2007) LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron 53, 703-717.
34. Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW (2004) Incipient Alzheimer's disease: Microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A 101, 2173-2178.
35. Yamaguchi H, Ishiguro K, Uchida T, Takashima A, Lemere CA, ImahoriK(1996) Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol 92, 232-241.
36. Imahori K, Uchida T (1997) Physiology and pathology of tau protein kinases in relation to Alzheimer's disease. J Biochem 121, 179-188.
37. Pei JJ, Tanaka T, Tung YC, Braak E, Iqbal K, Grundke-Iqbal I (1997) Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J Neuropathol Exp Neurol 56, 70-78.
38. Mc Donald JM, Savva GM, Brayne C, Welzel AT, Forster G, Shankar GM, Selkoe DJ, Ince PG, Walsh DM (2010) The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain 133, 1328-1341.
39. Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, Copeland NG, Price DL, Sisodia SS (1997) Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19, 939-945.
40. Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, Slunt HH,Wang R, Seeger M, Levey AI, Gandy SE, Copeland NG, Jenkins NA, Price DL, Younkin SG, Sisodia SS (1996) Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17, 1005-1013.
41. Tong XK, Lecrux C, Hamel E (2012) Age-dependent rescue by simvastatin of Alzheimer's disease cerebrovascular and memory deficits. J Neurosci 32, 4705-4715.
42. Hanger DP, Anderton BH, NobleW(2009) Tau phosphorylation: The therapeutic challenge for neurodegenerative disease. Trends Mol Med 15, 112-119.
43. Hardy JA, Higgins GA (1992) Alzheimer's disease: The amyloid cascade hypothesis. Science 256, 184-185.
44. Schmid AW, Lynch MA, Herron CE (2009) The effects of IL-1 receptor antagonist on beta amyloid mediated depression of LTP in the rat CA1 in vivo. Hippocampus 19, 670-676.
45. Costello DA, O'Leary DM, Herron CE (2005) Agonists of peroxisome proliferator-activated receptor-gamma attenuate the Abeta-mediated impairment of LTP in the hippocampus in vitro. Neuropharmacology 49, 359-366.
46. Duyckaerts C, Potier MC, Delatour B (2008) Alzheimer disease models and human neuropathology: Similarities and differences. Acta Neuropathol 115, 5-38.
47. Jankowsky JL, Slunt HH, Gonzales V, Jenkins NA, Copeland NG, Borchelt DR (2004) APP processing and amyloid deposition in mice haplo-insufficient for presenilin 1. Neurobiol Aging 25, 885-892.
48. Xiong H, Callaghan D, Wodzinska J, Xu J, Premyslova M, LiuQY, Connelly J, ZhangW(2011) Biochemical and behavioral characterization of the double transgenic mouse model (APPswe/PS1dE9) of Alzheimer's disease. Neurosci Bull 27, 221-232.
49. Garcia-Alloza M, Borrelli LA, Hyman BT, Bacskai BJ (2009) Antioxidants have a rapid and long-lasting effect on neuritic abnormalities in APP:PS1 mice. Neurobiol Aging 31, 2058-2068.
50. Scott L, Feng J, Kiss T, Needle E, Atchison K, Kawabe TT, Milici AJ, Hajos-Korcsok E, Riddell D, Hajos M (2012) Age-dependent disruption in hippocampal theta oscillation in amyloid-beta overproducing transgenic mice. Neurobiol Aging 33, 1481 e1413-1423.
51. Volianskis A, Kostner R, Molgaard M, Hass S, Jensen MS (2010) Episodic memory deficits are not related to altered glutamatergic synaptic transmission and plasticity in the CA1 hippocampus of the APPswe/PS1deltaE9-deleted transgenic mice model of ss-amyloidosis. Neurobiol Aging 31, 1173-1187.
52. Brown JT, Chin J, Leiser SC, Pangalos MN, Randall AD (2011) Altered intrinsic neuronal excitability and reduced Na+ currents in a mouse model of Alzheimer's disease. Neurobiol Aging 32, 2109 e2101-2114.
53. Minkeviciene R, Ihalainen J, Malm T, Matilainen O, Keksa-Goldsteine V, Goldsteins G, Iivonen H, Leguit N, Glennon J, Koistinaho J, Banerjee P, Tanila H (2008) Age-related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild-type mice. J Neurochem 105, 584-594.
54. Bliss TV, Collingridge GL (1993) A synaptic model of memory: Long-term potentiation in the hippocampus. Nature 361, 31-39.
55. Zhang W, Hao J, Liu R, Zhang Z, Lei G, Su C, Miao J, Li Z (2011) Soluble Abeta levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease. Behav Brain Res 222, 342-350.
56. Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, Wong MP, Price DL, Tang F, Markowska AL, Borchelt DR (2005) Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: Relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis 18, 602-617.
57. Morishima-Kawashima M, Ihara Y (1998) The presence of amyloid beta-protein in the detergent-insoluble membrane compartment of human neuroblastoma cells. Biochemistry 37, 15247-15253.
58. Stenh C, Englund H, Lord A, Johansson AS, Almeida CG, Gellerfors P, Greengard P, Gouras GK, Lannfelt L, NilssonLN (2005) Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay. Ann Neurol 58, 147-150.
59. Shankar GM, Welzel AT, McDonald JM, Selkoe DJ, Walsh DM(2011) Isolation of low-n amyloid beta-protein oligomers from cultured cells, CSF, and brain. Methods Mol Biol 670, 33-44.
60. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM (2009) Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 80, 13-17.
61. Shepardson NE, Shankar GM, Selkoe DJ (2011) Cholesterol level and statin use in Alzheimer disease: II. Reviewof human trials and recommendations. Arch Neurol 68, 1385-1392.
62. Vance JE (2012) Dysregulation of cholesterol balance in the brain: Contribution to neurodegenerative diseases. Dis Model Mech 5, 746-755.
63. Solomon A, Kivipelto M, Wolozin B, Zhou J, Whitmer RA (2009) Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. Dement Geriatr Cogn Disord 28, 75-80.
64. Vetrivel KS, Thinakaran G (2010) Membrane rafts in Alzheimer's disease beta-amyloid production. Biochim Biophys Acta 1801, 860-867.
65. HartmannT,Kuchenbecker J,GrimmMO(2007) Alzheimer's disease: The lipid connection. J Neurochem 103(Suppl 1), 159-170.
66. Ponce J, de la Ossa NP, Hurtado O, Millan M, Arenillas JF, Davalos A, Gasull T (2008) Simvastatin reduces the association ofNMDAreceptors to lipid rafts:Acholesterol-mediated effect in neuroprotection. Stroke 39, 1269-1275.
67. Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D (2009) Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 62, 788-801.
68. Cordle A, Landreth G (2005) 3-Hydroxy-3-methylglutarylcoenzyme A reductase inhibitors attenuate beta-amyloidinduced microglial inflammatory responses. J Neurosci 25, 299-307.
69. Clarke RM, O'Connell F, Lyons A, Lynch MA (2007) The HMG-CoA reductase inhibitor, atorvastatin, attenuates the effects of acute administration of amyloid-beta1-42 in the rat hippocampus in vivo. Neuropharmacology 52, 136-145.
70. Mans RA, Chowdhury N, Cao D, McMahon LL, Li L (2010) Simvastatin enhances hippocampal long-term potentiation in C57BL/6 mice. Neuroscience 166, 435-444.
71. Mans RA, McMahon LL, Li L (2012) Simvastatin-mediated enhancement of long-term potentiation is driven by farnesylpyrophosphate depletion and inhibition of farnesylation. Neuroscience 202, 1-9.
72. Ostrowski SM,Wilkinson BL, Golde TE, Landreth G (2007) Statins reduce amyloid-beta production through inhibition of protein isoprenylation. J Biol Chem 282, 26832-26844.
73. Snyder SW, Ladror US, Wade WS, Wang GT, Barrett LW, Matayoshi ED, Huffaker HJ, Krafft GA, Holzman TF (1994) Amyloid-beta aggregation: Selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys J 67, 1216-1228.
74. Kuperstein I, Broersen K, Benilova I, Rozenski J, JonckheereW, Debulpaep M, Vandersteen A, Segers-Nolten I, Van DerWerf K, Subramaniam V, Braeken D, Callewaert G, Bartic C, D'Hooge R, Martins IC, Rousseau F, Schymkowitz J, De Strooper B (2010) Neurotoxicity of Alzheimer's disease Abeta peptides is induced by small changes in the Abeta42 to Abeta40 ratio. EMBO J 29, 3408-3420.
75. Townsend M, Mehta T, Selkoe DJ (2007) Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem 282, 33305-33312.
76. Jope RS, Johnson GV (2004) The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29, 95-102.
77. ManHY,Wang Q, LuWY, JuW, Ahmadian G, Liu L, D'Souza S, Wong TP, Taghibiglou C, Lu J, Becker LE, Pei L, Liu F, Wymann MP, MacDonald JF, Wang YT (2003) Activation of PI3-kinase is required for AMPA receptor insertion during LTP of mEPSCs in cultured hippocampal neurons. Neuron 38, 611-624.
78. Mulkey RM, Malenka RC (1992) Mechanisms underlying induction of homosynaptic long-term depression in area CA1 of the hippocampus. Neuron 9, 967-975.
79. White AR, Du T, Laughton KM, Volitakis I, Sharples RA, Xilinas ME, Hoke DE, Holsinger RM, Evin G, Cherny RA, Hill AF, Barnham KJ, Li QX, Bush AI, Masters CL (2006) Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. J Biol Chem 281, 17670-17680.
80. Hye A,Kerr F, Archer N, FoyC, Poppe M, BrownR, Hamilton G, Powell J, Anderton B, Lovestone S (2005) Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease. Neurosci Lett 373, 1-4.
81. Hanger DP, Seereeram A, Noble W (2009) Mediators of tau phosphorylation in the pathogenesis of Alzheimer's disease. Expert Rev Neurother 9, 1647-1666.
82. Schaffer BA, Bertram L, Miller BL, Mullin K, Weintraub S, Johnson N, Bigio EH, Mesulam M, Wiedau-Pazos M, Jackson GR, Cummings JL, Cantor RM, Levey AI, Tanzi RE, Geschwind DH (2008) Association of GSK3B with Alzheimer disease and frontotemporal dementia. Arch Neurol 65, 1368-1374.
83. Avila J (2004) The influence of aging in one tauopathy: Alzheimer's disease. Arch Immunol Ther Exp (Warsz) 52, 410-413.
84. Avila J, Perez M, Lucas JJ, Gomez-Ramos A, Santa Maria I, Moreno F, Smith M, Perry G, Hernandez F (2004) Assembly in vitro of tau protein and its implications in Alzheimer's disease. Curr Alzheimer Res 1, 97-101.